• Explore /
  • Poster
  • / Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.

Abstract Poster

Authors

null

Gulam Abbas Manji

Columbia University Medical Center and New York-Presbyterian Hospital, New York, NY

Gulam Abbas Manji , Brian Andrew Van Tine , Shing Mirn Lee , Alexander Raufi , Parag Patwardhan , Lauren Esther Blumberg , Naomi Sender , Jennifer Wang , Daniel Otap , Shahnaz V. Singh-Kandah , Khanh Tu Do , Angela C. Hirbe , Gideon Bollag , Gary K. Schwartz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT02584647

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11055)

DOI

10.1200/JCO.2019.37.15_suppl.11055

Abstract #

11055

Poster Bd #

378

Abstract Disclosures

Similar Posters

First Author: Lee D. Cranmer

First Author: Abhishek Tripathi

First Author: Daniel E. Castellano

First Author: Elena Shagisultanova